Has metastatic cancer impacted your family or friends? On any given day in the US there are 550,000 people with metastatic cancer who have exhausted all primary therapies and have 36 months or less to live. We lost my father-in-law, Dean Bottlinger FTA '61, to metastatic eso****eal cancer.

There is a new therapy, called Tumor Treating Fields (TTF), which uses electric fields at specific frequencies to damage only the cancer cells while leaving surrounding cells unaffected. TTF causes only minor skin irritation with none of the debilitating side effects of chemo or radiation. Novocure (Nasdaq NVCR market cap $2B) has had successful FDA trials on primary tumors and generated over $600M in 2024 treating primarily glioblastoma. They used fixed arrays which can be successful with primary tumors but cannot adapt to metastatic disease.

A new company LifeBridge Innovations has patented Adaptive Tumor Treating Fields (ATTF) in which each electrode of the array is computer controlled allowing the field to be focused and multiple locations of the trunk can be treated at one time. They have completed 2000 hours of animal studies with no adverse events, and, if the trial is deemed successful by the FDA, the FDA has said that they will grant a basket trial for multiple types of solid cancers of the torso.

Multiple Aggie Docs are supporting this project. I am a physician and not an investment advisor, so I cannot give financial advice, but I am one of the docs that believes that this therapy could prolong the lives of hundreds of thousands of people with a good quality of life.

If you are an accredited investor, I can arrange a presentation with the CEO. Please DM me. If you would be interested in just owning a small amount, there is a crowdfund on WeFunder for $100 or more. Please share this information.

https://wefunder.com/lifebridgeinnovations

John Young, MD

Here is some UpToDate info on it... JUST FYI for those that want some objective info...

Subsequent-line therapy in non-small cell lung cancer lacking an actionable driver mutation

Investigational approaches Many strategies are being investigated in advanced NSCLC [16-21].


Tumor Treating Fields Tumor Treating Fields (TTFields) are electric fields that are delivered locoregionally and noninvasively to the tumor site via two pairs of array adhesive pads placed on the skin of the patient's thorax. The pulsed electrical fields slow tumor mitotic activity in the tumor by microtubule disruption. In a randomized trial in patients with progression on previous platinum-based chemotherapy, use of TTFields in addition to standard systemic therapy improved overall survival relative to systemic therapy alone (13.2 versus 9.9 months; HR 0.74, 95% CI 0.56-0.98), but increased the rate of serious adverse events (53 versus 38 percent) [20]. Several features limit the broad application of findings from this trial. Benefit observed was limited to the subset of patients who received TTFields with an immune checkpoint inhibitor in the second-line; benefit was not observed in those who received TTFields combined with docetaxel-based chemotherapy. However, in contemporary practice, immunotherapy is typically included in first-line treatment and not in later lines, outside of clinical trials. Moreover, treatment with TTFields requires energizing the system for at least 18 hours per day, requiring carrying a battery pack, which may impact patient mobility, and the adhesive pads can lead to skin reactions for sensitive patients.

The thing that worries me about investing in cancer treatments is that the big medical industrial complex has little interest in something that cuts into their cancer treatment profits. You always hear about the next big cancer treatment breakthrough that goes nowhere. The pharmaceutical industry is probably lobbying the FDA like crazy to shut this new treatment down. I hope I'm wrong though.

I'd have to wear this thing for 18 hours a day...forever?

would it be like a pacemaker, implanted and the battery replaced every x number of years?

Thunderstruck xx said:

---

The thing that worries me about investing in cancer treatments is that the big medical industrial complex has little interest in something that cuts into their cancer treatment profits. You always hear about the next big cancer treatment breakthrough that goes nowhere. The pharmaceutical industry is probably lobbying the FDA like crazy to shut this new treatment down. I hope I'm wrong though.

---

Don't worry, you're completely wrong. This is a baseless conspiracy theory that completely ignores the tens of billions that large pharmaceutical companies are burning on curative therapy R&D, early detection tests that will allow traditional therapies to cure a cancer, etc.

I just saw this reply -- we were out of town welcoming the newest future Ag to the family -- his dad is in TAMU med school.

This is commentary on a study done with the Novocure device. Novocure has performed multiple FDA trials which have ranged, in my opinion, from slight improvement to significant improvement in the primary cancer treated. I would encourage anyone interested to search "tumor treating fields cancer" at https://pubmed.ncbi.nlm.nih.gov/.

Novocure places a static electric field on each patient. LifeBridge was just awarded its sixth patent on advancements in TTF technology -- the field can now be moved and focused allowing for the treatment of multiple solid tumors of the torso at one time. I believe that the field strength will be high enough to significantly increase the effect on the tumors.

This technology is certainly worth studying. I have studied hundreds of hours and decided to support the company in its FDA studies. Over 2000 hours of animal studies have been performed on the LifeBridge Adaptive Tumor Treating Fields.

As always, DYOR (do your own research) - I am a physician and not an investment advisor.

John

The effectiveness increases with the length of treatment. Peter's wife with metastatic breast cancer, using a more rudimentary device like Novocure, was able to return to work as a neonatal nurse. She would put the unit on when she was at home -- evenings, nights, and weekends. She only experienced some warmth and minor tingling at the electrodes - there was no nausea, vomiting, weight loss, hair loss, etc. Since LifeBridge is able to focus the strength of the electric field, I will be very interested to see if ATTF is able to reduce the size or eliminate tumors entirely.

The FDA has been very helpful to LifeBridge. This is probably due to the successes of Novocure and the dire need for treatments to help patients with metastatic cancer. If the animal study (which is extensive and should conclude in 4 weeks) is successful, they have approved a "basket trial" for the pilot study of 36 metastatic cancer patients. This could lead, in the future, to an approval for treatment for every type of metastatic solid cancer in the torso that is included in the study, such as breast, ovarian, colon, lung, etc. This could dramatically reduce the time necessary to get this therapy to terminally ill metastatic patients.